Led · Equity · Oct 2023

Cirdan develops software and imaging solutions for pathology and laboratory diagnostics, including its flagship ULTRA LIS, a next-generation Laboratory Information System that scales from single-site labs to large multi-site laboratories. The company’s products aim to streamline operations, expedite disease diagnosis, and improve patient outcomes and healthcare efficiency. Cirdan’s solutions are deployed in over 200 clinical laboratories and hospitals across 20 countries and six continents. Headquartered in the UK with offices in Canada and Australia, the company was founded in 2010 in Lisburn, Ireland by Dr. Hugh Cormican and Stephen Dunniece. Cirdan plans to use new funding to accelerate delivery capabilities, expand its specialist team, enhance its product offerings, scale operations, and push further global expansion into new markets. Cirdan Imaging provides diagnostic digital health and imaging solutions designed to enhance and speed up patient clinical pathways and pathology laboratory work. Its platform includes specimen imaging solutions, patient and clinician apps, and a laboratory information system that collects critical information in a lean and fast way to reduce diagnostic time and surface new healthcare insights. The platform integrates with digital pathology and AI and is shown to improve efficiency, agility, control, and visibility in labs. Headquartered in the UK with offices in North America and Australia, the company serves clients in over 150 laboratories and hospitals across 20 countries and six continents. Cirdan is experiencing a period of rapid growth and intends to continue expanding with new innovative products and entry into new international markets. The company is led by Stephen Dunniece. Cirdan Imaging develops imaging and informatics technology aimed at accelerating and enhancing medical diagnosis. Its product portfolio includes the ULTRA laboratory information system (ULTRA LIS) and a suite of medical imaging systems. The company was established in 2010 and has additional offices in Canada and Australia. Cirdan employs 32 people and reports a multi‑million pound annual turnover. Growth has been driven in part by a 2013 acquisition of part of GE Healthcare’s business, which provided access to a blue‑chip global customer base. The company plans to use recent funding to strengthen ULTRA LIS, capitalize on a partnership with Kainos, scale operations, enter new markets and increase export sales. Cirdan Imaging develops, manufactures and supplies innovative medical imaging technology used in the diagnosis and management of disease. The company designs and distributes novel medical diagnostic solutions to healthcare customers. It was established in 2010 by CEO Hugh Cormican and CTO Stephen Dunniece and is based in Lisburn, Northern Ireland. Cirdan has been supported by Invest Northern Ireland through Co-Fund NI and QUBIS. Its customer base includes blue-chip companies in the UK, US, Canada, Australia and the Middle East. The company intends to use the recent investment to continue to expand operations.

Led · Equity · Mar 2022

Pilot Photonics develops patented photonic chip technology that uses laser light to generate exceptionally pure wireless signals for markets including AI data centers, satellite communications, and 5G/6G mobile networks. The company integrates photonic components into compact, production-scalable chips aimed at lowering size, weight, power, and cost barriers for critical industries, including commercial space (New Space). Pilot Photonics has received validation from leading international customers in both data-center and space markets. The EIC Accelerator award of up to €10.4 million is intended to fund product qualification, high-volume manufacturing, and expansion of the team in Ireland and internationally. The company is based in Dublin. The press release does not disclose revenue, user, or prior round metrics.

Led · Equity · Nov 2021

B-Secur has developed a patented software technique that uses an individual’s electrocardiogram (ECG) to enable secure identification while simultaneously providing health and wellness insights. The company embeds medical-grade ECG recording into consumer devices such as smartwatches, cars and clothing and is already selling to some of the world’s largest technology companies. B-Secur has been granted FDA clearance for its technology and has signed its first contract with a US-based medical device manufacturer. It employs over 45 scientists and engineers and has offices in Belfast’s Innovation Centre, Catalyst. The company intends to use new funding to cement traction in the wearable space, accelerate entry into the medical device market, and hire additional staff in Belfast and the US. B-Secur has developed a software technique that uses an individual’s unique heartbeat pattern (ECG) to securely identify users and deliver health and wellness insights. The company embeds this technology into smartwatches, cars and clothing and is already selling to some of the world’s largest technology companies. B-Secur has signed significant contracts with international customers in recent months. The company intends to use the new funds to expand its business reach. Led by CEO Alan Foreman, B-Secur is based in Belfast with offices in Belfast’s Innovation Centre, Catalyst, and employs over 35 scientists and engineers. It plans to hire additional staff in Belfast and engineering staff in customer regions including the US and China. Led by CEO Alan Foreman, B-Secur provides software solutions that use ECG/EKG biometrics for user authentication and to deliver health and wellness metrics. The company leverages the unique electrical signal of an individual's heartbeat (ECG) as a means of personal authentication and physiological monitoring. It launched the Heartkey brand at CES to combine unique user identification with medical-grade heart rate, stress and fatigue monitoring. Heartkey is being positioned for everyday applications such as in-vehicle monitoring and real-time health monitoring in the home, and for embedding in wearables. B-Secur is partnering with motoring manufacturers, global wearable and fitness tracker firms, and semiconductor manufacturers to integrate Heartkey into multiple technologies. The company employs more than 35 staff at its Belfast headquarters and recently closed a funding round to support expansion of its business reach. B-Secur develops a patented biometric technology that uses an individual’s unique heartbeat pattern (ECG) to authenticate identity. The company positions ECG as an internal biometric to reduce hacking and spoofing risks and improve security and convenience. Led by CEO Alan Foreman, B-Secur serves customers across automotive, financial services, access control, smart cities and buildings, and healthcare. Its semiconductor industry work is at the core of its technology development process. The company operates in the UK, Ireland and the US. B-Secur recently raised £3.5M to support growth and continued investment in science and engineering in Northern Ireland and beyond.

Led · Equity · Oct 2021

Kianda Technologies provides a cloud-based automation platform that enables users, with or without coding skills, to digitise and streamline business processes. The platform serves enterprises and counts over 25,000 users and international clients including Deme Group, Mercury, Uniphar and Aji Bio Pharma. Co-founded in 2016 by Osvaldo and Derya Sousa and based in Dublin, Ireland, Kianda sells its platform to international customers. The company intends to use the funds to continue to expand operations and broaden its business reach. It will also invest the proceeds to enhance product development and platform capabilities.

Participated · Series A · May 2021

Datactics, based in Belfast, provides an AI-enabled platform and services that let non-IT staff deduplicate, clean and enrich enterprise data. The platform is preconfigured for regulated sectors and the company serves clients in financial services and government agencies. Datactics says sales have grown strongly over the past twelve months and Par Equity notes revenues have more than doubled in the last two years; the company employs around 50 people. The firm will use the £2m funding to accelerate growth by investing in sales resources focused on London and New York and plans to put people in-market in New York and Tokyo before the end of the year. Management highlights the platform’s explainability as a selling point for risk‑averse customers. Datactics is a Belfast, Northern Ireland provider of RegTech solutions for the banking and financial services sector. Led by CEO Stuart Harvey, the company provides data quality and matching software to allow financial firms to measure, clean and match data ahead of regulatory reporting, business intelligence, or analytics processes. Its solutions combine data quality and matching capabilities with specialist regulatory knowledge to help multiple international Tier 1 financial firms comply with regulations including BCBS 239, MiFID II, and AML/KYC. The products are automated, customizable, connect to a wide range of data types and sources, and are designed for business users in banks, fund managers and government departments. The company is building upon an international customer base across Europe and the US and is opening two new offices in Milan and New York. It intends to use recent funding to facilitate R&D and hire additional key personnel.